Navigation Links
New Afatinib (BIBW 2992) Data in Non-Small Cell Lung Cancer Patients Presented at the 2010 ESMO Congress
Date:10/11/2010

ent options for physicians and their patients." 

About Lung Cancer

Lung cancer is the second most common cancer and kills more people than any other cancer.  In 2010, approximately 222,250 new cases of lung cancer will be diagnosed in the United States, with 157,300 Americans dying from the disease.   NSCLC is the most common form of lung cancer, accounting for about 85% of all lung cancers.(4)  Lung cancer remains an area of high unmet need, especially in its advanced stages where it is particularly aggressive and patients have limited treatment options. There is no FDA-approved therapy for patients with advanced lung cancer who have failed chemotherapy and progressed after treatment with an EGFR TKI.

About Afatinib's Clinical Trial Program: LUX Trial Program

The LUX trial program is a comprehensive and robust program that comprises more than 10 trials conducted across the globe, investigating afatinib in a variety of different solid tumor types, including NSCLC, breast and head and neck cancer.

LUX-Lung 1 is a phase IIb/III trial investigating afatinib plus best supportive care (BSC) versus placebo plus BSC in NSCLC patients who were previously treated with first-line chemotherapy and first-generation EGFR TKIs, erlotinib or gefitinib.

LUX-Lung 2 is a phase II trial evaluating afatinib in NSCLC patients with EGFR mutations, either treatment naïve or after one line of chemotherapy.

In two ongoing global phase III trials, LUX-Lung 3 and LUX-Lung 6, the efficacy and safety of afatinib is compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations in different geographical regions.

Another trial, LUX-Lung 5, is a global phase III trial in patients previously treated with erlotinib or gefitinib. This is the first randomized phase III trial investigating whether patients who initially benefit from treatment with afatinib alone may
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
8. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 2014 BerGenBio AS, a biopharmaceutical ... resistant cancers, today announces that it has raised NOK90 ... new and existing investors. BerGenBio will use ... of its pipeline of innovative cancer therapeutics, in particular ... candidate, BGB324, a first-in-class selective Axl kinase inhibitor, which ...
(Date:12/15/2014)... and Washington State are not the ... Oregon , Alaska , and ... November 2014 elections. Photo - http://photos.prnewswire.com/prnh/20141212/164152 ... The benefits of legalizing cannabis are manifold. There are ... tax revenue for state and local governments, in addition to ...
(Date:12/15/2014)...   DaVita HealthCare Partners Inc.  (NYSE: ... and most innovative health care communities, today announced ... Clinical Research  (DCR) and  HealthCare Partners Clinical Research , ... clinical research and data analytics services, specifically in ... renal disease (ESRD), as well as primary care ...
Breaking Medicine Technology:BerGenBio Completes NOK90 Million Fundraising 2CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4
... GAITHERSBURG, Md., June 27, 2011 /PRNewswire-USNewswire / -- ... new service for people with Acute Lymphoblastic Leukemia ... refund eligible patients 100 percent of any co-pay ... information on eligibility criteria, please call 1-800-490-3262, Monday ...
... of two studies testing drugs to slow or stop ... newly diagnosed with type 1 diabetes will be presented ... in San Diego and simultaneously published online in the ... National Institutes of Health,s international network of researchers, Type ...
Cached Medicine Technology:Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia 2Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia 3Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia 4Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes 2Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes 3Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes 4
(Date:12/15/2014)... Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s first full-time ... providing evidence on the impact of 100% pure fruit ... enough evidence already exists showing a negative link between ... the onset of tooth decay. One question that has ... fruit juice, meaning it is completely natural with no ...
(Date:12/15/2014)... OutMarket , a provider of ... Media Cheat Sheets ,” a guide that exposes the ... on the top ten social media networks. , ... awareness, engagement, and customer service. It can also increase ... impact on new networks and weather constantly changing algorithms, ...
(Date:12/15/2014)... -- Expert pilots process visual information more efficiently than ... decisions during landings, a new study shows. Landing ... to master, and 36 percent of all airplane crashes ... approach and landing. Researchers monitored the brain activity ... while they were at the controls of a flight ...
(Date:12/15/2014)... December 15, 2014 Emergo Group, Inc., ... 26 countries in North and South America, Europe, the ... from industry participants for its 2015 Medical Device Industry ... to identify upcoming business and market trends as well ... The survey targets areas including:, , ...
(Date:12/15/2014)... 15, 2014 Bacteroides is becoming the indicator ... it much more prevalent than coliforms, it cannot reproduce in ... environment. , Key Benefits of the new Bacteroides Sewage ... , Eliminates false positives from coliforms naturally occurring ... , Maintain the same sampling method with ...
Breaking Medicine News(10 mins):Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2
... Neurosurgeons from NYU Langone Medical Center will present research ... to treat neurosurgical conditions at the annual meeting of ... 14-18, 2012 in Miami Beach, FL. NYU Langone faculty ... at AANS, including: *Craino-Cervical and C1C2 Stabilization ...
... Virginia Commonwealth University School of Medicine researchers have discovered ... may contribute to high blood pressure and increase susceptibility to ... findings could provide clues to the best treatment approaches for ... can block blood flow to a pregnant woman,s internal organs ...
... Steven Reinberg HealthDay Reporter , THURSDAY, April ... called phthalates, which are found in soaps, lotions, plastics ... diabetes among older adults, Swedish researchers say. "Our ... contribute to the development of diabetes," said lead researcher ...
... , THURSDAY, April 12 (HealthDay News) -- Genetic evidence ... a new study says. The finding is significant because ... not, the researchers explained. The researchers compared the number ... life-cycle stage of head and body lice and found that ...
... in how exercise affects menopausal women, according to Penn ... one experiences more hot flashes after physical activity, while ... that seemed to differentiate the two groups was perceived ... of kinesiology. "These women have ways of dealing with ...
... Dotinga HealthDay Reporter , THURSDAY, April 12 (HealthDay ... stress, a new study from Denmark finds that the marriages ... likely to fall apart. The study debunks "a persistent ... one,s marriage and family. This is simply not true," said ...
Cached Medicine News:Health News:NYU Langone experts present research, clinical advances at neurosurgeons meeting 2Health News:Changes in gene expression may help explain high blood pressure in pregnancy 2Health News:Common Plastics Chemical Might Boost Diabetes Risk 2Health News:Common Plastics Chemical Might Boost Diabetes Risk 3Health News:Exercise and attitude may be thermostat for hot flashes 2Health News:Parents of Kids With Cancer No More Likely to Break Up 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: